--- a
+++ b/clusters/9knumclustersv2/clust_1530.txt
@@ -0,0 +1,15 @@
+Known allergy to any of the study agents or to compounds of similar chemical or biologic composition are excluded (including other somatostatin analogs)
+Known hypersensitivity to compounds of similar chemical composition to BMX-
+Known allergy to compounds of similar chemical or biologic composition to nivolumab
+Patients with known allergy to eggs or to compounds with a similar chemical or biologic composition to PROSTVAC or nivolumab
+Known allergy to compounds of similar chemical or biologic composition to nivolumab
+Known hypersensitivity to -fluorouracil, capecitabine, bevacizumab or to any component of the investigational products or compounds of similar chemical composition
+Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to lenalidomide, bortezomib and/or dexamethasone
+Poor tolerability or known allergy to lenalidomide, bortezomib and/or dexamethasone or compounds that have similar chemical or biologic composition to these study drugs
+History of hypersensitivity to LCI or to drugs of similar chemical classes.
+Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to dexamethasone, boron or mannitol
+Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to lenalidomide, bortezomib, panobinostat and/or dexamethasone
+Known hypersensitivity to -fluorouracil or to any component of the investigational products or compounds of similar chemical composition
+History of allergy or reaction attributed to compounds of chemical or biologic composition similar to those of MEDI- or AI
+Known or suspected allergy to any recombinant human antibodies, or compounds of similar chemical or biologic composition to sorafenib or any of the drugs in this study
+Subjects with history of hypersensitivity to compounds of similar chemical or biologic composition of XILONIX.